Recombinant NY‐ESO‐1 Cancer Antigen: Production and Purification under cGMP Conditions Academic Article uri icon

abstract

  • The cancer-testis antigen, NY-ESO-1, has been engineered into a bacterial expression plasmid which incorporates a His6-tag. The plasmid was transfected into E. coli strain BL21 and Master and Working cell banks generated from this expression system. Three 15-litre fermentations were performed under cGMP (code of Good Manufacturing Practice) conditions and the crude NY-ESO-1 tagged protein isolated as solubilised inclusion bodies. A three-step cGMP chromatography process (immobilised metal affinity, anion exchange, and hydrophobic interaction) was utilised to purify the protein. The purified NY-ESO-1 is being used in early stage human cancer vaccine trials in Australia and the U.S.A.

authors

  • Murphy, R
  • Green, S
  • Ritter, G
  • Cohen, L
  • Ryan, D
  • Woods, W
  • Rubira, M
  • Cebon, J
  • Davis, ID
  • Sjolander, A
  • Kypridis, A
  • Kalnins, H
  • McNamara, M
  • Moloney, MB
  • Ackland, J
  • Cartwright, G
  • Rood, J
  • Dumsday, G
  • Healey, K
  • Maher, D
  • Maraskovsky, E
  • Chen, Y‐T
  • Hoffman, EW
  • Old, LJ
  • Scott, AM

publication date

  • May 2005